Syneos Health completed the acquisition of Synteract for $403m.

Syneos Health, a fully integrated biopharmaceutical solutions organization, completed the acquisition of Synteract, a full-service CRO focused on the rapidly growing emerging biopharma segment, for $403m. "Synteract is one of the leading mid-sized, late-stage-focused CRO platforms with global reach and an attractive focus on the highest growth customer segment in the CRO space fueled by near-record funding levels. With Synteract, we will strengthen our leadership across the entire SMID category while we continue to drive growth among large biopharma customers. Importantly, we share operating and cultural philosophies built around finding the best combination of product, process and technology to fuel innovation. I look forward to welcoming Synteract to the Syneos Health family, as we collectively work to change patients’ lives," Alistair Macdonald, Syneos Health CEO.